Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

This case report describes a 35-year-old man who developed an atypical DRESS syndrome after taking topiramate for migraine prevention, which resolved with drug withdrawal and symptomatic treatment.

This study on Alzheimer's patients found that chronic sodium selenate treatment (up to 23 months) was safe and well-tolerated, with most adverse events being mild, and suggested potential slowing of cognitive decline, though confirmation requires further controlled studies.

This study found that spironolactone improved cognitive performance in patients with bipolar disorder experiencing manic episodes, but did not significantly affect manic symptoms, recommending further research with larger sample sizes and longer follow-ups.

This study found that intradermal QR678 Neo® therapy improved scalp condition in men and women with seborrheic dermatitis unresponsive to standard treatments, reducing flaking and inflammation after eight sessions, with high patient satisfaction reported.

The study found that patients with schizophrenia have a higher prevalence of skin diseases than those without, highlighting the importance of proper skin care in this population.

This study found that individuals with both schizophrenia and obesity showed reduced PER3 gene expression amplitude and lower melatonin levels compared to normal-weight controls, suggesting dampened circadian rhythms linked to irregular sleep. Hair follicle sampling was effective for assessing these molecular rhythms.

This study aimed to evaluate the effectiveness of a hair conditioner containing Serenoa serrulata extract and tocoferol applied 3-4 times per week for 90 days against androgenic alopecia.

A woman's hair grew back while she was taking sulphasalazine for arthritis.

This review discusses various oral drugs used for chronic central serous chorioretinopathy but reports no multi-center randomized clinical trials or long-term effect findings.

This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.

This case report describes a rare instance of gynecomastia in a male patient undergoing mirtazapine treatment for depression, suggesting the drug as a probable cause after ruling out other factors.

This study reports that valproic acid is effective in treating absence seizures and shows improvement in other types of seizures, though about 20% of patients experienced adverse effects.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

This study found that among anti-TNF-α agents, certolizumab is the least likely to cause paradoxical reactions such as psoriatic alopecia and appears to be an effective and safe option for managing psoriasis and PsA while minimizing these risks.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

The researchers reported that metabolism of progesterone to 3α,5α-THP in the hippocampus is important for its antiseizure effects in ovariectomized rats.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This correction clarifies the affiliations of researcher D. Piomelli in a case report on symptom improvement in a chronic psychotic patient treated with finasteride, without presenting new research findings.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

Raltegravir may cause hair loss in some patients.

This study suggests that 5alpha-dihydroprogesterone could be an effective, non-sedative anticonvulsant for drug-resistant complex partial seizures, as observed in a rat model.

This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.

TAK-279 effectively reduces psoriasis symptoms and is safe.

This study found that inhibiting the interaction between HOTAIR and EZH2 can block pro-fibrotic gene expression in fibroblasts and interfere with tissue remodeling in systemic sclerosis patient skin.

This case report documented an elderly woman with delusional parasitosis, a belief of being infested by parasites, which was associated with severe anemia and resolved significantly after anemia treatment and antipsychotic medication.